156 related articles for article (PubMed ID: 35920189)
1. Targeting PIM2 by JP11646 results in significant antitumor effects in solid tumors.
Katsuta E; Gil-Moore M; Moore J; Yousif M; Adjei AA; Ding Y; Caserta J; Baldino CM; Lee KP; Gelman IH; Takabe K; Opyrchal M
Int J Oncol; 2022 Oct; 61(4):. PubMed ID: 35920189
[TBL] [Abstract][Full Text] [Related]
2. Novel inhibition of PIM2 kinase has significant anti-tumor efficacy in multiple myeloma.
Nair JR; Caserta J; Belko K; Howell T; Fetterly G; Baldino C; Lee KP
Leukemia; 2017 Aug; 31(8):1715-1726. PubMed ID: 28008178
[TBL] [Abstract][Full Text] [Related]
3. Unique anti-myeloma activity by thiazolidine-2,4-dione compounds with Pim inhibiting activity.
Fujii S; Nakamura S; Oda A; Miki H; Tenshin H; Teramachi J; Hiasa M; Bat-Erdene A; Maeda Y; Oura M; Takahashi M; Iwasa M; Endo I; Yoshida S; Aihara KI; Kurahashi K; Harada T; Kagawa K; Nakao M; Sano S; Abe M
Br J Haematol; 2018 Jan; 180(2):246-258. PubMed ID: 29327347
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of PIM2 in liver cancer decreases tumor cell proliferation in vitro and in vivo primarily through the modulation of cell cycle progression.
Kronschnabl P; Grünweller A; Hartmann RK; Aigner A; Weirauch U
Int J Oncol; 2020 Feb; 56(2):448-459. PubMed ID: 31894300
[TBL] [Abstract][Full Text] [Related]
5. Protein kinase PIM2: A simple PIM family kinase with complex functions in cancer metabolism and therapeutics.
Wang Y; Xiu J; Ren C; Yu Z
J Cancer; 2021; 12(9):2570-2581. PubMed ID: 33854618
[TBL] [Abstract][Full Text] [Related]
6. Engineered Fully Human Single-Chain Monoclonal Antibodies to PIM2 Kinase.
Kaewchim K; Glab-Ampai K; Mahasongkram K; Chulanetra M; Seesuay W; Chaicumpa W; Sookrung N
Molecules; 2021 Oct; 26(21):. PubMed ID: 34770845
[TBL] [Abstract][Full Text] [Related]
7. Control of Pim2 kinase stability and expression in transformed human haematopoietic cells.
Adam K; Lambert M; Lestang E; Champenois G; Dusanter-Fourt I; Tamburini J; Bouscary D; Lacombe C; Zermati Y; Mayeux P
Biosci Rep; 2015 Oct; 35(6):. PubMed ID: 26500282
[TBL] [Abstract][Full Text] [Related]
8. PIM2 interacts with tristetraprolin and promotes breast cancer tumorigenesis.
Ren C; Yang T; Qiao P; Wang L; Han X; Lv S; Sun Y; Liu Z; Du Y; Yu Z
Mol Oncol; 2018 May; 12(5):690-704. PubMed ID: 29570932
[TBL] [Abstract][Full Text] [Related]
9. Positive regulation of PFKFB3 by PIM2 promotes glycolysis and paclitaxel resistance in breast cancer.
Lu C; Qiao P; Sun Y; Ren C; Yu Z
Clin Transl Med; 2021 Apr; 11(4):e400. PubMed ID: 33931981
[TBL] [Abstract][Full Text] [Related]
10. Proviral insertion in murine lymphomas 2 promotes stomach cancer progression by regulating apoptosis via reactive oxygen species-triggered endoplasmic reticulum stress.
Xin H; Deng Y; Cao J
Biochem Biophys Res Commun; 2018 Nov; 506(1):145-152. PubMed ID: 30340823
[TBL] [Abstract][Full Text] [Related]
11. Abrine promotes cell proliferation and inhibits apoptosis of interleukin-1β-stimulated chondrocytes via PIM2/VEGF signalling in osteoarthritis.
Meng Y; Yin D; Qiu S; Zhang X
Phytomedicine; 2022 Feb; 96():153906. PubMed ID: 35026522
[TBL] [Abstract][Full Text] [Related]
12. Fructose-1, 6-bisphosphatase 1 interacts with NF-κB p65 to regulate breast tumorigenesis via PIM2 induced phosphorylation.
Lu C; Ren C; Yang T; Sun Y; Qiao P; Han X; Yu Z
Theranostics; 2020; 10(19):8606-8618. PubMed ID: 32754266
[No Abstract] [Full Text] [Related]
13. Phosphorylation of HSF1 by PIM2 Induces PD-L1 Expression and Promotes Tumor Growth in Breast Cancer.
Yang T; Ren C; Lu C; Qiao P; Han X; Wang L; Wang D; Lv S; Sun Y; Yu Z
Cancer Res; 2019 Oct; 79(20):5233-5244. PubMed ID: 31409638
[TBL] [Abstract][Full Text] [Related]
14. PIM2 promotes hepatocellular carcinoma tumorigenesis and progression through activating NF-κB signaling pathway.
Tang X; Cao T; Zhu Y; Zhang L; Chen J; Liu T; Ming X; Fang S; Yuan YF; Jiang L; Huang JD; Guan XY
Cell Death Dis; 2020 Jul; 11(7):510. PubMed ID: 32641749
[TBL] [Abstract][Full Text] [Related]
15. Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers.
Garcia PD; Langowski JL; Wang Y; Chen M; Castillo J; Fanton C; Ison M; Zavorotinskaya T; Dai Y; Lu J; Niu XH; Basham S; Chan J; Yu J; Doyle M; Feucht P; Warne R; Narberes J; Tsang T; Fritsch C; Kauffmann A; Pfister E; Drueckes P; Trappe J; Wilson C; Han W; Lan J; Nishiguchi G; Lindvall M; Bellamacina C; Aycinena JA; Zang R; Holash J; Burger MT
Clin Cancer Res; 2014 Apr; 20(7):1834-45. PubMed ID: 24474669
[TBL] [Abstract][Full Text] [Related]
16. PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma.
Gómez-Abad C; Pisonero H; Blanco-Aparicio C; Roncador G; González-Menchén A; Martinez-Climent JA; Mata E; Rodríguez ME; Muñoz-González G; Sánchez-Beato M; Leal JF; Bischoff JR; Piris MA
Blood; 2011 Nov; 118(20):5517-27. PubMed ID: 21937691
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Pim2-prolonged skin allograft survival through the apoptosis regulation pathway.
Liu H; Zhang C; Liang T; Song J; Hao J; Hou G
Cell Mol Immunol; 2012 Nov; 9(6):503-10. PubMed ID: 23085945
[TBL] [Abstract][Full Text] [Related]
18. PIM2-mediated phosphorylation of hexokinase 2 is critical for tumor growth and paclitaxel resistance in breast cancer.
Yang T; Ren C; Qiao P; Han X; Wang L; Lv S; Sun Y; Liu Z; Du Y; Yu Z
Oncogene; 2018 Nov; 37(45):5997-6009. PubMed ID: 29985480
[TBL] [Abstract][Full Text] [Related]
19. PIM2 kinase is induced by cisplatin in ovarian cancer cells and limits drug efficacy.
Musiani D; Hammond DE; Cirillo L; Erriquez J; Olivero M; Clague MJ; Di Renzo MF
J Proteome Res; 2014 Nov; 13(11):4970-82. PubMed ID: 25099161
[TBL] [Abstract][Full Text] [Related]
20. CIP2A is a target of bortezomib in human triple negative breast cancer cells.
Tseng LM; Liu CY; Chang KC; Chu PY; Shiau CW; Chen KF
Breast Cancer Res; 2012 Apr; 14(2):R68. PubMed ID: 22537901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
